|
|
|
| home > white papers > PhlexEview: Transforming Costly Paper Processes into Value Driven Compliance - Phlexglobal Ltd |
|
|
 WHITE PAPERS |
|
Phlexglobal Ltd
|
|
PhlexEview: Transforming Costly Paper Processes into Value Driven Compliance
|
|
Phlexglobal, the TMF experts, have developed PhlexEview, its best of breed electronic Trial Master File (eTMF) system that supports efficient management and tracking of TMF content throughout the lifecycle of a clinical trial. PhlexEview transforms costly, stagnant, paper-based processes into dynamic, value driven compliance programs by capturing, tracking and managing global TMF activities and enabling unprecedented access to trial content throughout the conduct of the study.
Compliance is always the most critical factor when designing an approach to TMF management. But that doesn’t mean that an organisation has to spend time and money managing paper that does not support global access, collaboration or compliance efforts. PhlexEview supports compliance and collaboration by leveraging industry standards and making TMF content available to users, regardless of their location.
The ability to access and view TMF content at any time transforms sluggish and inert paper processes and helps organisations to realise time and cost savings by reducing travel costs, positioning team members to proactively identify compliance issues and implement corrective actions and by facilitating global collaboration. This paper discusses some of the challenges of traditional paper-based TMFs and provides details about PhlexEview. It also suggests a new approach to TMF compliance that extracts and sets the expectation for continuing value from TMF content, rather than locking it away in paper storage where its value is minimised.
|
|
|
|
|
|
|
|
 |
News and Press Releases |
 |
PredictImmune announce issuance of new patent in the US in support of commercialisation
PredictImmune, developers of pioneering prognostic tools for guiding
treatment options and improving patient outcomes in immune-mediated
diseases, today confirmed its latest patent grant in the US. The US
patent is part of PredictImmune’s third family of intellectual property
(IP) relating to methods for predicting autoimmune disease risk. This
follows successful grants across the company’s first family of IP in the
UK and Europe in October 2018 and Canada in January this year.
More info >> |
|
 |
White Papers |
 |
|
Maximize the ROI of Your Post-Approval Research
Bioclinica
Expenditures in post-approval (Phase IV) research are going up across the pharmaceutical, biotech and medical device industries. Given the resources you’ve committed to post-approval research, you may be wondering if you’re getting the greatest possible return on your investment.
Discover how to harness the power of post-approval research to increase data collection, reduce resource burn, save money, and maximize your ROI!
More info >> |
|
 |
Industry Events |
 |
BioTrinity 2019
30 April - 1 May 2019, etc.venues 155 Bishopsgate, London EC2M 3YD
BioTrinity 2019 is taking
place from the 30th April – 1stMay at etc.venues 155 Bishopsgatein London. Now in its 13th year, BioTrinity remains the leading Life Sciences Biopartnering
and Investment conference in Europe, and generates unrivalled opportunities for
life science companies, academics, investors, and major pharmaceutical players
to come together to do deals and establish collaborations.
More info >> |
|
|
|
